Replies to post #115713 on Biotech Values

[ciotera]

Odd that they don't mention that AVEO's tivozanib deal was with Astellas.

[DewDiligence]

Roche submits PLX4032 NDA/MAA for BRAF-V600+ melanoma:

http://finance.yahoo.com/news/New-Drug-Applications-bw-1675487810.html?x=0&.v=1

PLX4032 (a/k/a vemurafenib) is the drug Roche licensed from Plexxikon that was the subject of a recent series in the NY Times (#msg-46899517, #msg-54567652). The phase-3 data (#msg-58950046) were sufficiently compelling that Daiichi Sanko bought Plexxikon for almost $1B two months ago (#msg-60475592).